#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Paroxysmal nocturnal haemoglobinuria Hyperphagia Loss of consciousness Squamous cell carcinoma of the vulva Tourette's disorder Chronic kidney disease Piriformis syndrome Anal squamous cell carcinoma Pseudoxanthoma elasticum B-cell lymphoma Porphyria non-acute Optic glioma Hyperinsulinaemic hypoglycaemia Neuroblastoma recurrent Pyruvate dehydrogenase complex deficiency More trials…

    Learn about Rare Diseases

    Rosai-Dorfman syndrome – Diagnostics Proteus syndrome – Diagnostics Pelizaeus-Merzbacher disease – Life with Disease Acute respiratory distress syndrome – Treatment Synovial sarcoma recurrent – Basic Information Cerebral arteriovenous malformation haemorrhagic – Life with Disease Alexander disease – Diagnostics Adrenogenital syndrome – Life with Disease Haemophilia A with anti factor VIII – Basic Information Behcet’s syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fampridine Cilgavimab PARECOXIB Cpk850 Belinostat Idelalisib Naloxone Hydrochloride Blu-263 Phosphate Azilsartan Medoxomil Burfiralimab SC0062 Palonosetron Other Immunosuppressants ALLO-QUADCAR01-T BUDOPRUTUG ZILEBESIRAN Leuprorelin Acetate Venlafaxine Rondaptivon Pegol Collagenase More therapies…

    Learn about Your Condition

    Left ventricular dysfunction Critical illness Systemic infection Lung adenocarcinoma stage IV Testis cancer Herpes simplex Ewing's sarcoma metastatic Ebola disease Arteriospasm coronary Erythema multiforme Organ donor Naevus flammeus Peyronie's disease Cerebral palsy BK virus infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Lutetium (177Lu) Vipivotide Tetraxetan
    • Abiraterone Acetate
    • Gozetotide
    Austria Belgium Czechia France Germany The Netherlands +3

  • Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Ceralasertib
    • Docetaxel
    • Durvalumab
    Belgium France Germany Hungary Ireland Italy +4

  • Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    Investigated Drugs:
    • Domvanalimab
    • Durvalumab
    • Infliximab
    Belgium France Germany Greece Hungary Italy +4

  • Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Atezolizumab
    Belgium Czechia France Germany Greece Ireland +3

  • Study comparing brigatinib alone versus brigatinib with carboplatin and pemetrexed combination as first treatment for patients with advanced ALK-positive lung cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IIIB
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Brigatinib
    • Carboplatin
    • Pemetrexed
    France

  • Study of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Anal squamous cell carcinoma
    • Penile squamous cell carcinoma
    • Squamous cell carcinoma of the cervix
    Investigated Drugs:
    • Vorinostat
    • Pembrolizumab
    France

  • Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Epirubicin Hydrochloride
    • Anastrozole
    • Cyclophosphamide
    Belgium France Germany Italy Poland Portugal +1

  • Study on the Effectiveness of Apalutamide in Men with Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Abiraterone Acetate
    • Apalutamide
    • Prednisone
    Austria Belgium Czechia Denmark France Germany +6

  • Study on the Safety and Effects of Livmoniplimab and Budigalimab in Patients with Advanced or Metastatic Solid Tumors

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Malignant mast cell neoplasm
    Investigated Drugs:
    • Budigalimab
    • Livmoniplimab
    Belgium France Germany Italy Poland Spain

  • Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Cyclophosphamide
    Austria Belgium Bulgaria France Germany Hungary +3
Previous Page
1 … 13 14 15 16 17 … 20
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!